최신 재무제표(Form-10K)에 따르면, Simulations Plus Inc의 총 자산은 $0이며, 순損失입니다.
SLP의 주요 재무 비율은 무엇인가요?
Simulations Plus Inc의 유동비율은 0이고, 순이익률은 0, 주당 매출은 $0입니다.
Simulations Plus Inc의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
Simulations Plus Inc の最大収益セグメントは Insurance Agency で、最新の利益発表における収益は 100,823,592 です。地域別に見ると、China が Simulations Plus Inc の主要市場であり、収益は 108,262,390 です。
Simulations Plus Inc은 수익성이 있나요?
いいえ, 최신 재무제표에 따르면 Simulations Plus Inc의 순損失은 $0입니다.
Simulations Plus Inc에 부채가 있나요?
いいえ, Simulations Plus Inc의 부채는 0입니다.
Simulations Plus Inc의 발행 주식은 몇 주인가요?
Simulations Plus Inc의 총 발행 주식은 0주입니다.
主要データ
前終値
$18.14
始値
$18.18
当日レンジ
$18.04 - $18.21
52週レンジ
$11.09 - $28.44
取引高
1.0M
平均取引高
334.9K
配当利回り
0.00%
1株当たり利益(TTM)
-3.12
時価総額
$364.5M
SLPとは何ですか?
Simulations Plus, Inc. engages in the provision of software and consulting services supporting drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. The company is headquartered in Research Triangle Park, North Carolina and currently employs 212 full-time employees. The firm helps its clients by accelerating the discovery, development, and commercialization of pharmaceuticals and other products through science-based software and consulting solutions. The Company’s segments include Software and Services. The firm's Software segment supports pharmaceutical research, development, and commercialization through simulation, modeling, and AI-driven prediction. Its main products include GastroPlus, ADMET Predictor, MonolixSuite, and others for disease modeling and training, as well as Pro-ficiency for clinical operations. Its Services segment includes advanced consulting services across the entire drug development lifecycle. Its scientists and engineers specialize in drug discovery, pharmacokinetics, pharmacodynamics, drug modeling, clinical trial data analysis, regulatory strategy, and medical communications.